Zfra1-31

WW domain-containing oxidoreductase 1 (WWOX) inhibitor

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

1.	Hyperglycemia 08/19/2022 - "Our findings also support the efficacy of Zfra1-31 in treating hyperglycemia/diabetes-associated neurodegeneration."
2.	Neoplasms (Cancer) 06/01/2017 - "Synthetic peptides Zfra1-31 and Zfra4-10 are known to effectively block the growth of many types of cancer cells. " 02/28/2015 - "Here, we determined that when nude mice and BALB/c mice were pre-injected with nanogram levels of a synthetic Zfra1-31 or truncated Zfra4-10 peptide via tail veins, these mice became resistant to the growth, metastasis and stemness of melanoma cells, and many malignant cancer cells. "
3.	Neuroblastoma 08/19/2022 - "Our experiments were mainly performed in differentiated SH-SY5Y neuroblastoma cells exposed to high glucose and treated (or not) with Zfra1-31, the specific inhibitor of WWOX. "
4.	Neoplasm Metastasis (Metastasis) 02/28/2015 - "Here, we determined that when nude mice and BALB/c mice were pre-injected with nanogram levels of a synthetic Zfra1-31 or truncated Zfra4-10 peptide via tail veins, these mice became resistant to the growth, metastasis and stemness of melanoma cells, and many malignant cancer cells. "
5.	Melanoma (Melanoma, Malignant) 02/28/2015 - "Here, we determined that when nude mice and BALB/c mice were pre-injected with nanogram levels of a synthetic Zfra1-31 or truncated Zfra4-10 peptide via tail veins, these mice became resistant to the growth, metastasis and stemness of melanoma cells, and many malignant cancer cells. "